Comparison of Clinical Outcomes in Patients with Active Cancer Receiving Rivaroxaban or Low-Molecular-Weight Heparin: The OSCAR-UK Study.
Alexander T CohenChristopher WallenhorstMarcella RiveraCihan AyBernhard SchaeferKhaled AbdelgawwadGeorge PsaroudakisGunnar BrobertAnders EkbomAgnes Y Y LeeAlok A KhoranaCecilia BecattiniMarc CarrierCraig I ColemanCarlos MartinezPublished in: Thrombosis and haemostasis (2024)
Patients with CT, not at high risk of bleeding, treated with either rivaroxaban or LMWH have comparable effectiveness and safety outcomes. This supports the recommendation that rivaroxaban is a reasonable alternative to LMWH for the treatment of CT.
Keyphrases
- venous thromboembolism
- atrial fibrillation
- pulmonary embolism
- image quality
- computed tomography
- dual energy
- contrast enhanced
- papillary thyroid
- positron emission tomography
- magnetic resonance imaging
- squamous cell carcinoma
- metabolic syndrome
- cross sectional
- type diabetes
- young adults
- combination therapy
- newly diagnosed
- weight loss
- smoking cessation
- glycemic control